B. Riley FBR analyst Madhu Kumar raised his price target for Tetraphase Pharmaceuticals to $7 following the FDA approval of Xerava. The drug’s broad label and reasonable pricing should support a rapid U.S. launch, Kumar tells investors in a research note. He reiterates a Buy rating on Tetraphase.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.